Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma.

Bharathy N, Berlow NE, Wang E, Abraham J, Settelmeyer TP, Hooper JE, Svalina MN, Ishikawa Y, Zientek K, Bajwa Z, Goros MW, Hernandez BS, Wolff JE, Rudek MA, Xu L, Anders NM, Pal R, Harrold AP, Davies AM, Ashok A, Bushby D, Mancini M, Noakes C, Goodwin NC, Ordentlich P, Keck J, Hawkins DS, Rudzinski ER, Chatterjee B, Bächinger HP, Barr FG, Liddle J, Garcia BA, Mansoor A, Perkins TJ, Vakoc CR, Michalek JE, Keller C.

Sci Signal. 2018 Nov 20;11(557). pii: eaau7632. doi: 10.1126/scisignal.aau7632.

PMID:
30459282
2.

Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.

Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, Hashimoto A, Vonteddu P, Behera R, Goins MA, Mulligan C, Nam B, Hockstein N, Denstman F, Shakamuri S, Speicher DW, Weeraratna AT, Chao T, Vonderheide RH, Languino LR, Ordentlich P, Liu Q, Xu X, Lo A, Puré E, Zhang C, Loboda A, Sepulveda MA, Snyder LA, Gabrilovich DI.

Cancer Cell. 2017 Nov 13;32(5):654-668.e5. doi: 10.1016/j.ccell.2017.10.005.

3.

Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.

Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S, Chintala S, Ordentlich P, Kao C, Elzey B, Gabrilovich D, Pili R.

Clin Cancer Res. 2017 Sep 1;23(17):5187-5201. doi: 10.1158/1078-0432.CCR-17-0741. Epub 2017 Jul 11.

4.

Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.

Simmons JK, Michalowski AM, Gamache BJ, DuBois W, Patel J, Zhang K, Gary J, Zhang S, Gaikwad S, Connors D, Watson N, Leon E, Chen JQ, Kuehl WM, Lee MP, Zingone A, Landgren O, Ordentlich P, Huang J, Mock BA.

Mol Cancer Ther. 2017 Sep;16(9):2008-2021. doi: 10.1158/1535-7163.MCT-17-0171. Epub 2017 May 18.

5.

Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.

Torres-Adorno AM, Lee J, Kogawa T, Ordentlich P, Tripathy D, Lim B, Ueno NT.

Clin Cancer Res. 2017 Aug 15;23(16):4780-4792. doi: 10.1158/1078-0432.CCR-16-2622. Epub 2017 May 2.

6.

The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat.

Tomita Y, Lee MJ, Lee S, Tomita S, Chumsri S, Cruickshank S, Ordentlich P, Trepel JB.

Oncoimmunology. 2016 Aug 31;5(11):e1219008. doi: 10.1080/2162402X.2016.1219008. eCollection 2016.

7.

ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.

Batlevi CL, Kasamon Y, Bociek RG, Lee P, Gore L, Copeland A, Sorensen R, Ordentlich P, Cruickshank S, Kunkel L, Buglio D, Hernandez-Ilizaliturri F, Younes A.

Haematologica. 2016 Aug;101(8):968-75. doi: 10.3324/haematol.2016.142406. Epub 2016 May 5.

8.

Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer.

Merino VF, Nguyen N, Jin K, Sadik H, Cho S, Korangath P, Han L, Foster YMN, Zhou XC, Zhang Z, Connolly RM, Stearns V, Ali SZ, Adams C, Chen Q, Pan D, Huso DL, Ordentlich P, Brodie A, Sukumar S.

Cancer Res. 2016 Apr 1;76(7):2013-2024. doi: 10.1158/0008-5472.CAN-15-1619. Epub 2016 Jan 19.

9.

A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.

Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P, Ueno NT.

Breast Cancer Res Treat. 2014 Jul;146(2):259-72. doi: 10.1007/s10549-014-3014-7. Epub 2014 Jun 12.

10.

HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.

Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B.

Cancer Res. 2009 Nov 1;69(21):8403-11. doi: 10.1158/0008-5472.CAN-09-2146. Epub 2009 Oct 13.

11.

The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.

Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, Ordentlich P, Wang XF, Counter CM, Yao TP.

Cancer Res. 2008 Sep 15;68(18):7561-9. doi: 10.1158/0008-5472.CAN-08-0188.

12.

Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor alpha.

Busch BB, Stevens WC Jr, Martin R, Ordentlich P, Zhou S, Sapp DW, Horlick RA, Mohan R.

J Med Chem. 2004 Nov 4;47(23):5593-6.

PMID:
15509154
13.

Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand.

Willy PJ, Murray IR, Qian J, Busch BB, Stevens WC Jr, Martin R, Mohan R, Zhou S, Ordentlich P, Wei P, Sapp DW, Horlick RA, Heyman RA, Schulman IG.

Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8912-7. Epub 2004 Jun 7.

14.

Nurr1-RXR heterodimers mediate RXR ligand-induced signaling in neuronal cells.

Wallen-Mackenzie A, Mata de Urquiza A, Petersson S, Rodriguez FJ, Friling S, Wagner J, Ordentlich P, Lengqvist J, Heyman RA, Arenas E, Perlmann T.

Genes Dev. 2003 Dec 15;17(24):3036-47. Epub 2003 Dec 17.

15.

Identification of the antineoplastic agent 6-mercaptopurine as an activator of the orphan nuclear hormone receptor Nurr1.

Ordentlich P, Yan Y, Zhou S, Heyman RA.

J Biol Chem. 2003 Jul 4;278(27):24791-9. Epub 2003 Apr 22.

16.
17.

A natural product that lowers cholesterol as an antagonist ligand for FXR.

Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD.

Science. 2002 May 31;296(5573):1703-6. Epub 2002 May 2.

18.

Sharp, an inducible cofactor that integrates nuclear receptor repression and activation.

Shi Y, Downes M, Xie W, Kao HY, Ordentlich P, Tsai CC, Hon M, Evans RM.

Genes Dev. 2001 May 1;15(9):1140-51.

19.

Corepressors and nuclear hormone receptor function.

Ordentlich P, Downes M, Evans RM.

Curr Top Microbiol Immunol. 2001;254:101-16. Review. No abstract available.

PMID:
11190569
20.

Identification of a nuclear domain with deacetylase activity.

Downes M, Ordentlich P, Kao HY, Alvarez JG, Evans RM.

Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10330-5.

21.
22.

The transcriptional basis of steroid physiology.

Lin RJ, Kao HY, Ordentlich P, Evans RM.

Cold Spring Harb Symp Quant Biol. 1998;63:577-85. Review. No abstract available.

PMID:
10384323
23.

Unique forms of human and mouse nuclear receptor corepressor SMRT.

Ordentlich P, Downes M, Xie W, Genin A, Spinner NB, Evans RM.

Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2639-44.

24.

A histone deacetylase corepressor complex regulates the Notch signal transduction pathway.

Kao HY, Ordentlich P, Koyano-Nakagawa N, Tang Z, Downes M, Kintner CR, Evans RM, Kadesch T.

Genes Dev. 1998 Aug 1;12(15):2269-77.

25.

Human deltex is a conserved regulator of Notch signalling.

Matsuno K, Eastman D, Mitsiades T, Quinn AM, Carcanciu ML, Ordentlich P, Kadesch T, Artavanis-Tsakonas S.

Nat Genet. 1998 May;19(1):74-8.

PMID:
9590294
26.

Notch inhibition of E47 supports the existence of a novel signaling pathway.

Ordentlich P, Lin A, Shen CP, Blaumueller C, Matsuno K, Artavanis-Tsakonas S, Kadesch T.

Mol Cell Biol. 1998 Apr;18(4):2230-9.

27.
28.

HMG box-activating factors 1 and 2, two HMG box transcription factors that bind the human Ig heavy chain enhancer.

Stevens S, Ordentlich P, Sen R, Kadesch T.

J Immunol. 1996 Oct 15;157(8):3491-8.

PMID:
8871648
29.

Secretion of lysosomal enzymes by drug-sensitive and multiple drug-resistant cells.

Warren L, Jardillier JC, Ordentlich P.

Cancer Res. 1991 Apr 15;51(8):1996-2001.

Supplemental Content

Loading ...
Support Center